Holen Sie sich die Stockscreener-App
9.46
2.49%
0.23
Handel nachbörslich:
9.36
-0.10
-1.06%
Schlusskurs vom Vortag:
$9.23
Offen:
$9.1
24-Stunden-Volumen:
90,730
Relative Volume:
0.10
Marktkapitalisierung:
$151.45K
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-15.46%
1M Leistung:
-94.71%
6M Leistung:
-99.61%
1J Leistung:
-99.91%
1-Tages-Spanne:
$9.10
$9.73
1-Wochen-Bereich:
$9.10
$11.68
52-Wochen-Spanne:
$6.71
$17,908.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Firmenname
Cero Therapeutics Holdings Inc
Sektor
Branche
Telefon
650-407-2376
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie CERO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
9.46 | 151.45K | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc Aktie (CERO) Neueste Nachrichten
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Dow Dips Around 300 Points As Israel-Iran Conflict Escalates: Investor Sentiment Declines, Fear & Greed Index Moves To 'Neutral' Zone - Benzinga
CERo Therapeutics stock soars after FDA grants Orphan Drug Designation By Investing.com - Investing.com India
CERo Therapeutics stock soars after FDA grants Orphan Drug Designation - Investing.com
Sector Update: Health Care - MarketScreener
Crude Oil Rises Sharply; Jabil Earnings Top Views - Benzinga
CERo Therapeutics (CERO) Stock Explodes Over 200% in a Landmark Trading Day - Daily Chhattisgarh News
CERO Trading Halted Due to Market Volatility | CERO Stock News - GuruFocus
CERo Therapeutics Says CER-1236 Gets FDA Orphan Drug Designation in Acute Myeloid Leukemia - marketscreener.com
US Stocks Lower; Retail Sales Decline In May - Benzinga
CERO Trading Resumes: Key Developments and Insights | CERO Stock News - GuruFocus
What's Going On With Cero Therapeutics Stock Tuesday? - Benzinga
Cero Therapeutics announces FDA ODD granted to CER-1236 - TipRanks
CERo Therapeutics Gains FDA Orphan Drug Designation - TipRanks
CERo Therapeutics Gets Orphan Drug Status For CER-1236 In Acute Myeloid Leukemia - Nasdaq
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug - GlobeNewswire
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) - Yahoo
FDA Grants Orphan Status to CeroTherapeutics' Acute Myeloid Leukemia Drug | CERO Stock News - GuruFocus
Cero Therapeutics treatment of leukemia granted orphan designation - TipRanks
CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements - TipRanks
CERo Therapeutics announces 1-for-20 reverse stock split effective June 13 - MSN
Trading Halted for CERO; Anticipated Announcement Pending | CERO Stock News - GuruFocus
Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance
CERO Announces One-for-Twenty Reverse Stock Split | CERO Stock N - GuruFocus
CERo Therapeutics to implement 1-for-20 reverse stock split By Investing.com - Investing.com South Africa
CERo Therapeutics to implement 1-for-20 reverse stock split - Investing.com Australia
CERo Therapeutics Announces Reverse Stock Split - TipRanks
CERo Therapeutics Holdings, Inc. Announces One-for-Twenty Reverse Stock Split Effective June 13, 2025 - Nasdaq
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split - GlobeNewswire
CERo Therapeutics Sets Major 1:20 Reverse Split, Shares Consolidate 95% Next Week - Stock Titan
CERo Therapeutics issues additional Series D stock By Investing.com - Investing.com South Africa
CERo Therapeutics Completes Series D Stock Issuance - TipRanks
CERO Expands Series D Preferred Stock Offering to Raise Capital - GuruFocus
CERo Therapeutics issues additional Series D stock - Investing.com
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing - The Manila Times
CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million - Nasdaq
CERo Therapeutics Lands $3M Series D Extension as CAR-T Cancer Trial Shows Promise - Stock Titan
CERo Therapeutics regains Nasdaq compliance - MSN
Cero announces two granted U.S. patents, European patent application allowance - Yahoo Finance
CERo Therapeutics secures key patents for cancer therapy By Investing.com - Investing.com South Africa
CERo Therapeutics Expands Leadership with New Executive Roles - TipRanks
Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO) - Insider Monkey
CERO Therapeutics Expands Patent Portfolio with New U.S. and Eur - GuruFocus
CERo Therapeutics secures key patents for cancer therapy - Investing.com Australia
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 - The Globe and Mail
CERo Therapeutics Holds 18 Patents and Applications Expanding Immunotherapy Portfolio - Nasdaq
CERo Therapeutics Secures 18 Global Patents for Revolutionary Cancer-Fighting Cell Therapy Technology - Stock Titan
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial - MSN
CERo Therapeutics (NASDAQ:CERO) Rating Lowered to “Hold” at D Boral Capital - Defense World
CERo Therapeutics (NASDAQ:CERO) Receives “Hold” Rating from D. Boral Capital - Defense World
Finanzdaten der Cero Therapeutics Holdings Inc-Aktie (CERO)
Es liegen keine Finanzdaten für Cero Therapeutics Holdings Inc (CERO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Cero Therapeutics Holdings Inc-Aktie (CERO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 13 '24 |
Sale |
0.06 |
2,998,908 |
179,934 |
13,005,169 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
| SLOAN STUART M | 10% Owner |
Sep 25 '24 |
Sale |
0.10 |
532,486 |
55,538 |
21,067,956 |
| YK Bioventures Opportunities G | 10% Owner |
Oct 10 '24 |
Sale |
0.10 |
3,250,000 |
325,000 |
22,620,783 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):